Compare Recursion Pharmaceuticals Inc (RXRX) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Financial Select Sector SPDR Fund — how do they compare? Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B), while Financial Select Sector SPDR Fund trades at $54.34 (market cap $50.06B). The key difference: Financial Select Sector SPDR Fund is far larger — about 23.4× Recursion Pharmaceuticals Inc's market cap, and Financial Select Sector SPDR Fund is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| RXRX | XLF | |
|---|---|---|
Market Cap | $2.14B | $50.06B |
Volume | 30,789,535 | 47,464,120 |
Sector | Health | — |
52-Week High | $6.79 | $58.55 |
52-Week Low | $2.84 | $47.80 |
Typical Hold Time | 22 Days | 104 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
XLF trades at $53.75, down 0.48% with bearish technical signals from moving averages. The financial sector faces headwinds as bank stocks lag the S&P 500 by the widest margin since 1990 despite rising profits. Recent Fed stress test changes and interest rate hikes create a mixed environment for financial institutions, with higher rates potentially benefiting some sector components while increasing borrowing costs.
The ETF's concentrated exposure to 76 large-cap financial firms positions it for potential gains from rising rates, though sector underperformance and regulatory uncertainty present near-term challenges. Fund managers increased financial allocations in Q2 2026, suggesting institutional confidence in the sector's rate sensitivity advantages over tech stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
